Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2019 |
| Outros Autores: | , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/32451 |
Resumo: | 2020-04-01 |
| id |
CRUZ_ace93c323860e70e9df1b8e5006cc9f8 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/32451 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Dooley, Kelly E.Kaplan, RichardMwelase, NoluthandoGrinsztejn, BeatrizTicona, EduardoLacerda, MarcusSued, OmarBelonosova, ElenaAit-Khaled, MounirAngelis, KonstantinosBrown, DannaeSingh, RajendraTalarico, Christine L.Tenorio, Allan R.Keegan, Michael R.Aboud, Michael2019-04-11T12:35:59Z2019-04-11T12:35:59Z2019DOOLEY, Kelly E. et al. Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial. Clinical Infectious Diseases, p. 1-20, Mar. 2019.1058-4838https://www.arca.fiocruz.br/handle/icict/3245110.1093/cid/ciz2561537-6591engOxford University PressDolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trialinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2020-04-01Johns Hopkins University School of Medicine. Center for Tuberculosis Research. Baltimore, MD, USA.Desmond Tutu HIV Foundation. Cape Town, South Africa.Clinical HIV Research Unit. Johannesburg, South Africa.Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.Hospital Nacional Dos de Mayo. Lima, Peru / Universidad Nacional Mayor de San Marcos. Lima, Peru.Fundação Oswaldo Cruz. Instituto Leônidas e Maria Deane. Manaus, AM, Brasil /Tropical Medicine Foundation Dr Heitor Vieira Dourado. Manaus, AM, Brazil.Fundación Huésped. Buenos Aires, Argentina.Regional Center For Prevention and Treatment of AIDS and Infectious Diseases. Moscow, Russia.ViiV Healthcare Ltd. Brentford, UK.GlaxoSmithKline. Stockley Park. Uxbridge, UK.ViiV Healthcare Ltd. Melbourne, Victoria, Australia.GlaxoSmithKline. Collegeville, PA, USA.ViiV Healthcare. Research Triangle Park. NC, USA.ViiV Healthcare. Research Triangle Park. NC, USA.ViiV Healthcare Ltd. Brentford, UK.ViiV Healthcare Ltd. Brentford, UK.Background: Concurrent treatment of tuberculosis and HIV is challenging owing to drug interactions, overlapping toxicities, and immune reconstitution inflammatory syndrome (IRIS). The efficacy and safety of dolutegravir were assessed in adults with HIV and drug-susceptible tuberculosis. Methods: INSPIRING (NCT02178592) is a non-comparative, active-control, randomised, open-label study in HIV1-infected ART-naïve adults (CD4+ 50 cells/mm3 ). Participants on rifampicin-based tuberculosis treatment ≤8 weeks were randomised (3:2) to receive dolutegravir (50 mg twice-daily during and 2 weeks post-tuberculosis therapy, then 50 mg once-daily) or efavirenz (600 mg daily), with two NRTIs for 52 weeks. The primary endpoint was the proportion of dolutegravir-arm participants with plasma HIV-1-RNA <50 copies/mL (responders) by FDA Snapshot algorithm (intent-to-treat exposed population) at Week 48. The study was not powered to compare arms. Results: For dolutegravir (N=69), Baseline HIV-1-RNA was >100,000 copies/mL in 64%, with median CD4+ 208 cells/mm3 ; for efavirenz (N=44), 55% had HIV-1-RNA >100,000 copies/mL, median CD4+ count was 202 cells/mm3 . Week 48 response rate was 75% (52/69) (95% CI: 65%, 86%) for dolutegravir and 82% (36/44) (95% CI: 70%, 93%) for efavirenz. Dolutegravir non-response was driven by non-treatmentrelated discontinuations (n=10 lost-to-follow-up). There were no deaths or study drug switches. There were two discontinuations for toxicity (efavirenz). There were three protocol-defined virological failures (2 dolutegravir, no acquired resistance; 1 efavirenz, NRTI and NNRTI emergent resistance). Tuberculosis treatment success was high. TB-associated IRIS was uncommon (4/arm), with no discontinuations for IRIS. Conclusions: Among adults with HIV receiving rifampicin-based tuberculosis treatment, twice-daily dolutegravir was effective and well-tolerated.HIVTuberculosisDolutegravirEfavirenzImmune reconstitution inflammatory syndromeinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALDOLUTEGRAVIR-BASED_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2019.pdfDOLUTEGRAVIR-BASED_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2019.pdfapplication/pdf910864https://www.arca.fiocruz.br/bitstream/icict/32451/2/DOLUTEGRAVIR-BASED_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2019.pdf215deeb033bb4cffb56d8cc51cca3830MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/32451/3/license.txt5a560609d32a3863062d77ff32785d58MD53TEXTDOLUTEGRAVIR-BASED_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2019.pdf.txtDOLUTEGRAVIR-BASED_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2019.pdf.txtExtracted texttext/plain43107https://www.arca.fiocruz.br/bitstream/icict/32451/4/DOLUTEGRAVIR-BASED_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2019.pdf.txt228a180af56e6404f19020711e198802MD54icict/324512021-03-24 16:32:30.28oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-03-24T19:32:30Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial |
| title |
Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial |
| spellingShingle |
Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial Dooley, Kelly E. HIV Tuberculosis Dolutegravir Efavirenz Immune reconstitution inflammatory syndrome |
| title_short |
Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial |
| title_full |
Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial |
| title_fullStr |
Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial |
| title_full_unstemmed |
Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial |
| title_sort |
Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial |
| author |
Dooley, Kelly E. |
| author_facet |
Dooley, Kelly E. Kaplan, Richard Mwelase, Noluthando Grinsztejn, Beatriz Ticona, Eduardo Lacerda, Marcus Sued, Omar Belonosova, Elena Ait-Khaled, Mounir Angelis, Konstantinos Brown, Dannae Singh, Rajendra Talarico, Christine L. Tenorio, Allan R. Keegan, Michael R. Aboud, Michael |
| author_role |
author |
| author2 |
Kaplan, Richard Mwelase, Noluthando Grinsztejn, Beatriz Ticona, Eduardo Lacerda, Marcus Sued, Omar Belonosova, Elena Ait-Khaled, Mounir Angelis, Konstantinos Brown, Dannae Singh, Rajendra Talarico, Christine L. Tenorio, Allan R. Keegan, Michael R. Aboud, Michael |
| author2_role |
author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Dooley, Kelly E. Kaplan, Richard Mwelase, Noluthando Grinsztejn, Beatriz Ticona, Eduardo Lacerda, Marcus Sued, Omar Belonosova, Elena Ait-Khaled, Mounir Angelis, Konstantinos Brown, Dannae Singh, Rajendra Talarico, Christine L. Tenorio, Allan R. Keegan, Michael R. Aboud, Michael |
| dc.subject.en.pt_BR.fl_str_mv |
HIV Tuberculosis Dolutegravir Efavirenz Immune reconstitution inflammatory syndrome |
| topic |
HIV Tuberculosis Dolutegravir Efavirenz Immune reconstitution inflammatory syndrome |
| description |
2020-04-01 |
| publishDate |
2019 |
| dc.date.accessioned.fl_str_mv |
2019-04-11T12:35:59Z |
| dc.date.available.fl_str_mv |
2019-04-11T12:35:59Z |
| dc.date.issued.fl_str_mv |
2019 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
DOOLEY, Kelly E. et al. Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial. Clinical Infectious Diseases, p. 1-20, Mar. 2019. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/32451 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1058-4838 |
| dc.identifier.doi.none.fl_str_mv |
10.1093/cid/ciz256 |
| dc.identifier.eissn.none.fl_str_mv |
1537-6591 |
| identifier_str_mv |
DOOLEY, Kelly E. et al. Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial. Clinical Infectious Diseases, p. 1-20, Mar. 2019. 1058-4838 10.1093/cid/ciz256 1537-6591 |
| url |
https://www.arca.fiocruz.br/handle/icict/32451 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Oxford University Press |
| publisher.none.fl_str_mv |
Oxford University Press |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/32451/2/DOLUTEGRAVIR-BASED_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2019.pdf https://www.arca.fiocruz.br/bitstream/icict/32451/3/license.txt https://www.arca.fiocruz.br/bitstream/icict/32451/4/DOLUTEGRAVIR-BASED_Beatriz_Grinsztejn_INI_Lapclin-AIDS_2019.pdf.txt |
| bitstream.checksum.fl_str_mv |
215deeb033bb4cffb56d8cc51cca3830 5a560609d32a3863062d77ff32785d58 228a180af56e6404f19020711e198802 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009202873892864 |